A 52-year-old man with a known diagnosis of WHO Grade II diffuse astrocytoma (IDH-mutant) completed initial surgery 6 months ago. He now presents with worsening headaches and focal neurological deficits. Contrast-enhanced MRI shows enlargement of the residual tumor with new ring enhancement and central necrosis. Which investigation is most appropriate to differentiate tumor recurrence from radiation necrosis?

Explanation

## Investigation of Choice for Differentiating Tumor Recurrence from Radiation Necrosis **Key Point:** Advanced PET imaging (11C-methionine or 18F-FDG) is the most specific investigation to differentiate true tumor recurrence from radiation-induced necrosis in patients with prior glioma treatment. ### Why PET Imaging is Correct PET with 11C-methionine or 18F-FDG provides: 1. **Metabolic differentiation** — recurrent tumor shows high uptake (increased amino acid metabolism or glucose consumption); radiation necrosis shows low or absent uptake 2. **Superior specificity** — PET can distinguish viable tumor from non-viable necrotic tissue, which conventional MRI cannot reliably do 3. **Prognostic value** — high uptake correlates with aggressive recurrence and guides treatment intensity **High-Yield:** In the post-treatment setting (especially after radiotherapy), conventional MRI alone cannot reliably differentiate tumor recurrence from radiation necrosis because both show contrast enhancement and edema. PET is the gold standard for this distinction [cite:Harrison 21e Ch 375]. ### Comparison of Investigations | Investigation | Recurrence Pattern | Necrosis Pattern | Utility | |---|---|---|---| | **PET (11C-Met or 18F-FDG)** | High uptake | Low/absent uptake | **Gold standard** for differentiation | | **PWI/DTI (advanced MRI)** | High rCBV, restricted diffusion | Low rCBV, high diffusion | Useful but less specific than PET | | **Conventional MRI (serial)** | Progressive enhancement, edema | Stable or slowly resolving | Cannot reliably differentiate; requires interval follow-up | | **CSF analysis** | Elevated tumor markers | Normal/low markers | Low sensitivity; not standard for this indication | **Clinical Pearl:** In resource-limited settings where PET is unavailable, advanced MRI techniques (perfusion-weighted imaging showing elevated relative cerebral blood volume [rCBV], diffusion-weighted imaging) can provide supportive evidence, but PET remains the reference standard. ### Mechanism of Differentiation ```mermaid flowchart TD A[Post-treatment glioma with new enhancement on MRI]:::outcome --> B{Differential diagnosis}:::decision B -->|Recurrent tumor| C[High metabolic activity]:::action B -->|Radiation necrosis| D[Low metabolic activity]:::action C --> E[PET: High 11C-Met or 18F-FDG uptake]:::outcome D --> F[PET: Low/absent uptake]:::outcome E --> G[Proceed to salvage therapy]:::action F --> H[Conservative management, repeat imaging]:::action ``` **Mnemonic: PET-RN** — PET differentiates Recurrence from Necrosis: - **Recurrence** = High uptake (viable tumor metabolism) - **Necrosis** = Low uptake (dead tissue, no metabolism)